Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINRITSAN 2: Rituximab for Maintenance of Remission in ANCA-associated Vasculitis
NCT01731561Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2012
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of relapses at 28 months. Started Nov 2012; status: completed.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT01731561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731561.